https://www.live-feeds.com/feed/revolution-medicines-pancreatic-cancer-drug-has-stunning-commercial-debutContinuously updated, source-cited coverage. https://www.live-feeds.com/feed/revolution-medicines-pancreatic-cancer-drug-has-stunning-commercial-debuthttps://www.live-feeds.com/feed/revolution-medicines-pancreatic-cancer-drug-has-stunning-commercial-debut#u186930Mon, 09 Nov 2026 03:01:09 +0000Revolution Medicines' pancreatic cancer drug, Rasonque, has generated $198 million in sales over five weeks. The company's stock has risen due to the drug's strong performance. Revolution Medicines is focused on developing targeted medicines for RAS-addicted cancers. The drug's commercial debut has been described as 'eye-popping' by some analysts.Why it mattersThe company's success is significant in the field of pancreatic cancer treatment, where there is a high unmet medical need. Pancreatic cancer is a aggressive disease with limited treatment options. Revo